CLINICAL AND THERAPEUTIC STUDIES IN HUMAN FILARIASIS

伊维菌素已经在南印度和其他地方的试验中被证明是 Bancroftian对清除微丝虫病非常有效 丝虫病。印度南部和巴西目前的研究(与 世界其他地方的足迹)专注于开发一种养生方法来 优化微丝虫病清除持续时间。 最近的研究表明，热带肺嗜酸性粒细胞增多症 综合征既可由线虫引起，也可由线虫引起。工作到 鉴别这两种肺嗜酸性粒细胞增多症 适当的治疗正在进行中。 地方病流行地区的外籍游客中的血吸虫病的特征是 对丝虫病有明显的临床和免疫高反应性 寄生虫。假想的低反应状态，包括临床和 免疫学上，在地方性流行区的感染者中 西非贝宁的研究已经证明了这一点。一种治疗方法 阿苯达唑治疗血吸虫病的试验也在那里进行。

Ivermectin has been shown in trials in both South India and elsewhere to be very effective in clearing microfilaremia in patients with bancroftian filariasis. Current studies in South India and Brazil (coordinated with trail elsewhere in the world) are focussed on developing a regimen to optimize the duration of microfilarial clearance. Recent investigation has indicated that the Tropical Pulmonary Eosinophilia syndrome can be caused by strongyloides as well as by filariae. Work to differentiate these two pulmonary eosinophilic conditions and develop appropriate therapy is underway. Loiasis in expatriate visitors to endemic areas has been characterized as having marked clinical and immunologic hyperresponsiveness to the filarial parasite. The hypothesized state of hyporesponsiveness, both clinical and immunological, in infected individuals native to the endemic regions has now been demonstrated by studies in Benin, West Africa. A therapeutic trial of albendazole for loiasis is also underway there.